iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

iRhythm Technologies Inc.

In a report released today, David Roman from Goldman Sachs maintained a Hold rating on Irhythm Technologies, with a price target of $147.00. Accord...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IRTC	$115.36	-2.37%	183.54K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IRTC	$115.36	-2.4%	183.54K
3
4
5
6

IRTC

IRTC

Get iRhythm Technologies Inc. Data in Excel

Get iRhythm Technologies Inc. Data in Excel